Incorporating Cytarabine in Pre-treatment for Haploidentical Stem Cell Transplantation in Extramedullary Acute Leukemia: Safety and Efficacy
Allogeneic hematopoietic stem cell transplantation is among the most effective methods for treating malignant hematopoietic tumors. However, for extramedullary leukemia, even with high-intensity chemotherapy and transplantation, the recurrence rate remains high. To improve the prognosis, it's essential to optimize the pre-treatment plan and reduce recurrence.At this EBMT annual meeting,Dr. Min Xiong from Hebei Yanda Ludaopei Hospital reported a clinical study (Abstract No.: 1100). Results indicate that a pre-treatment regimen incorporating cytarabine for haploidentical hematopoietic stem cell transplantation to treat extramedullary leukemia is both safe and effective. We've invited Dr. Xiong for a interpretation of this research.
This retrospective analysis was conducted on 36 patients with extramedullary leukemia who underwent haploidentical allogeneic hematopoietic stem cell transplantation at Beijing Ludaopei Hospital from August 2019 to March 2022. The pre-treatment regimen used BU/CY in 14 cases (38.9%) and TBI/CY in 22 cases (61.1%), combined with cytarabine (5 mg/kg, on days -3 and -2). The overall survival (OS), disease-free survival (DFS), and transplant-related mortality (TRM) of the patients were assessed.